Hoffmann-La Roche Inc.

Arrowhead Madison, Inc.

Genentech, Inc.

F. Hoffmann-La Roche Ag

Arrowhead Pharmaceuticals, Inc.

Kerstin Jahn-Hofmann

Peter Mohr

David B Rozema

Philipp Hadwiger

David L Lewis

Torsten Hoffmann

Eric Argirios Kitas

Hans Martin Mueller

Ingo Roehl

Guenther Ott

Jon Asher Wolff

Darren H Wakefield

Andrei V Blokhin

Jeffrey Carlson

Jonathan D Benson

Eric A Kitas

Jeffrey C Carlson

Guy Georges

Ulrich Brinkmann

Olaf Mundigl

Birgit Bramlage

Werner Scheuer

Eike Hoffmann

Hugues Matile

Alexander Haas

Matthias John

Rebecca Croasdale

Ludger Ickenstein

Jan Olaf Stracke

Silke Metz

Michael Grote

Haiyan Wang

Sannah Zoffmann Jensen

Wilma Dormeyer

Ingo Röhl

Simone Dill

Torsten Hoffman

Cristiano Migliorini

Günther Ott

Ludger Markus Ickenstein

Jon A Wolff

The invention provides novel compounds and conjugates of these compounds useful for the delivery of biologically active substances. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to a delivery polymer to achieve in vivo mRNA knock down are disclosed therein.

Small molecule conjugates for intracellular delivery of biologically active compounds

The invention provides use of novel compounds for delivery of nucleic acids, and conjugates of these compounds with nucleic acids. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to said compounds and co-administered with a delivery polymer to achieve mRNA knock down in vivo are disclosed therein.

Small molecule conjugates for intracellular delivery of nucleic acids

The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.

Peptide-based in vivo siRNA delivery system

This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.

Bi-specific digoxigenin binding antibodies

The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.

In vivo polynucleotide delivery conjugates having enzyme sensitive linkages

The present invention relates to an antibody directed to a beta cell marker protein, in particular to an antibody directed to the protein TMEM27.

Tmem27 antibody

Growing community of inventors

Neu-Isenburg, Germany

Kerstin Jahn-Hofmann